A University of Rochester Medical Center study shows that when tumors are treated with radiotherapy, the benefits can be hijacked by the treatment's counteraction to trigger inflammation and dampen the body's immune response.

Published by the journal Oncotarget, the study suggests that radiotherapy (also known as radiation treatment) could be more effective if it was combined with a drug that would block a specific cell that is responsible for dulling the immune system. In mice, the research team experimented by delivering an immunotherapy two days prior to radiotherapy and saw significant benefits for many different types of cancer.

Led by Scott A. Gerber, Ph.D., assistant professor in the Department of Surgery, and graduate student Kelli A. Connolly, the research fills an important gap in knowledge. Scientists already know that radiotherapy stimulates anti-tumor cells and helps to control cancer's growth. What is less understood is why radiotherapy cannot cure cancer.

The answer may lie with how the immune system responds to radiotherapy when a tumor is present. The URMC and Wilmot Cancer Institute scientists discovered that radiation increases the circulation of certain harmful inflammatory cells and changes the way the immune system rallies against cancer. In many patients, the circulating level of these cells (called monocytes) is already high prior to cancer treatment and sometimes indicates a poor prognosis.

Gerber believes that the abundance of these cells, which can be measured in a simple blood test, could identify patients who might benefit most from blocking them, allowing the immune system to fight the disease in combination with radiotherapy. Because these inflammatory cells express a unique protein on their surface, they are an easy target for medications, the study said. "Our observations of what happens during radiotherapy when cells are recruited to the tumor site and surrounding tissue has intriguing implications for how to improve treatment," said Gerber, who also has an appointment in the URMC Department of Microbiology and Immunology.

For more information: www.urmc.rochester.edu


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 30, 2024 — RaySearch Laboratories AB announced the release of the latest version of RayCare, the next generation ...

Time May 30, 2024
arrow
Subscribe Now